AbbVie
ABBV
#27
Rank
NZ$654.43 B
Marketcap
NZ$370.29
Share price
1.17%
Change (1 day)
14.16%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2025 (TTM): NZ$2.32

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$2.24. In 2024 the company made an earnings per share (EPS) of NZ$4.02 a decrease over its 2023 EPS that were of NZ$4.56.

EPS history for AbbVie from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$2.32-42.43%
2024NZ$4.02-11.86%
2023NZ$4.56-58.95%
2022NZ$11.122.49%
2021NZ$10.85121.58%
2020NZ$4.89-44.7%
2019NZ$8.8545.84%
2018NZ$6.079.72%
2017NZ$5.53-9.54%
2016NZ$6.1116.28%
2015NZ$5.26184.1%
2014NZ$1.85-57.15%
2013NZ$4.32

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.86 27.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$34.07 1,417.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$21.64 863.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$18.25 712.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$10.83 382.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$4.93 119.70%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$5.04 124.51%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$5.97 166.00%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$7.16 218.82%๐Ÿ‡บ๐Ÿ‡ธ USA